Background and Aim: Metformin has been shown to have anti-cytokine property. Lipopolysaccharide (LPS)-induced or repeated water avoidance stress (WAS)-induced visceral allodynia and increased gut permeability were pro-inflammatory cytokine-dependent responses, which were considered to be animal models of irritable bowel syndrome (IBS). We hypothesized that metformin improves symptoms in the patients with IBS by attenuating these visceral changes and tested the hypothesis in rats. Methods: The threshold of the visceromotor response induced by colonic balloon distention was measured. Colonic permeability was determined in vivo by quantifying the absorbed Evans blue for 15 min spectrophotometrically. Results: Subcutaneously injected LPS (1 mg/kg) reduced the threshold of visceromotor response, and metformin (5-50 mg/kg for 3 days) intraperitoneally attenuated this response in a dose-dependent manner. Repeated WAS (1 h daily for 3 days) induced visceral allodynia, which was also blocked by metformin. The antinociceptive effect of metformin on the LPS-induced allodynia was reversed by compound C, an adenosine monophosphate-activated protein kinase inhibitor or N
Introduction
Disturbed visceral sensorimotor function is believed to play a pivotal role in the pathophysiology of irritable bowel syndrome (IBS). Additionally, the importance of the impaired gut permeability with abnormal immune response has been recently recognized. 1 The increased levels of plasma pro-inflammatory cytokines and serum lipopolysaccharide (LPS) are detected in IBS. [2] [3] [4] Moreover, LPSinduced stimulation of cytokines release from peripheral blood mononuclear cells is enhanced, and higher symptoms severity such as urgency and diarrhea are associated with higher cytokines response induced by LPS. 5 We previously confirmed that LPS (immune stress) or repeated water avoidance stress (WAS; psychological stress) induced visceral allodynia via interleukin (IL)-1 and IL-6 pathways, 6, 7 which are considered to be experimental animal models for IBS. In this context, inhibiting cytokine signaling may be a promising approach for the treatment of this disease.
Metformin is a well-known antidiabetic agent that improves peripheral insulin sensitivity via an adenosine monophosphateactivated protein kinase (AMPK)-dependent mechanism. 8, 9 On the other hand, nonglycemic effects of metformin have been also reported, including improved endothelial function, neuroprotection, and reduced tumorigenesis. 10 Several studies demonstrated that the drug inhibited pro-inflammatory cytokine release from endothelial cells, smooth muscle cells, and macrophage. 11, 12 Incidentally, activating AMPK signaling by metformin exhibits antinociceptive action against somatic pain in several animal pain models. 13, 14 Metformin also reverses the elevated gut permeability and serum LPS level in high-fat fed mice. 15 However, there is no study exploring the effect of metformin on visceral sensation or altered gut permeability induced by stress.
We hypothesized that metformin is beneficial for treating IBS by improving visceral sensation and gut permeability via suppressing cytokine signaling. In this study, we attempted to determine the effect of metformin on visceral allodynia and increased gut permeability induced by LPS or repeated WAS in rats to examine the hypothesis.
controlled conditions of illumination (12 h light/dark cycle starting at 7 a.m.) with temperature regulated at 23-25°C. The Rats were allowed free access to standard food (Solid rat chow, Oriental Yeast, Tokyo, Japan) and tap water.
Chemicals. Metformin hydrochloride (LKT Laboratories Inc., St. Paul, MN, USA); LPS obtained from Escherichia coli with the serotype 055:B5 (Sigma-Aldrich, St. Louis, MO, USA); N G -nitro-L-arginine methyl ester (L-NAME), a nitric oxide (NO) synthesis inhibitor; naloxone hydrochloride, an opioid receptor antagonist and domperidone (Wako Pure Chemical Industries, Osaka, Japan), a peripheral dopamine D2 receptor antagonist were dissolved in normal saline. Sulpiride (Wako Pure Chemical Industries), a dopamine D2 receptor antagonist and compound C (dorsomorphin, LC laboratories Inc., Woburn, MA, USA), an AMPK inhibitor was dissolved in dimethyl sulfoxide.
Measuring visceral sensation. Visceral sensation was assessed by abdominal muscle contractions induced by colonic distention (visceromotor response [VMR]) using electromyogram (EMG) in conscious rats, which was validated as quantitative measure of visceral nociception. 16 Implanting electrodes and placing colonic distention balloon. Under brief ether anesthesia, electrodes (Teflon coated stainless steel, 0.05-mm diameter, MT Giken, Tokyo, Japan) for EMG were inserted approximately 2 mm into the left side external oblique musculature through small skin incision in non-fasted rats. They were fixed to the musculature by cyanoacrylate instant adhesive together with the incised skin. The electrode leads were externalized directly through this closed incision. A distension balloon (6-Fr disposable silicon balloon-urethral catheter, JU-SB0601; Terumo Corporation, Tokyo, Japan) was inserted intra-anally with the distal end positioned 2 cm proximal to the anus.
Colonic distention and measuring abdominal muscle contractions. After completing electrodes implantation and balloon placement, the rats were placed in Bollmann cages and acclimated to the experimental condition for 30 min. The electrode leads were then connected to an EMG amplifier, and EMG signals were amplified, digitized by a PowerLab system (AD Instruments, Colorado Springs, CO, USA), and recorded using computer software (LabChart 7, AD Instruments). Colonic distension was performed according to previous publications, 6, 7, 17 namely, ascending method of limits phasic distension was applied in increments of 0.1 mL for 5 s by inflating the balloon by water using a Figure 1 (a) The threshold of visceromotor response (VMR) was determined by the distended balloon volume (mL) inducing apparent sustained abdominal muscle contractions. Demonstrable electromyogram (EMG) recording is depicted. The threshold of VMR was 0.4 mL in this rat. (b) Schematic representation of the experimental protocol to explore the effect of metformin on lipopolysaccharide (LPS)-induced visceral allodynia. The basal VMR threshold was measured at 30 min after the surgery for implanting EMG electrodes and placing the balloon, and LPS (1 mg/kg) or the vehicle was administered. Later, the surgery and balloon placement were performed again, and the threshold was measured at 3 h after the injection. Metformin or the vehicle was injected thrice at 48 h, 24 h, and 30 min before injection of LPS. (c) The protocol for determining the effect of metformin on repeated water avoidance stress-induced visceral allodynia. The basal threshold was measured at 30 min after the surgery. Then the rats were subjected to either water avoidance stress or sham stress for 1 h daily for three consecutive days. The second threshold measurement was performed at 24 h after the last stress session. Metformin or the vehicle was injected 4 times, that is, at Metformin improves visceral pain syringe manually until significant abdominal muscle contractions, that is, VMR, were detected (Fig. 1a) . The VMR threshold was defined as the distended balloon volume (mL) inducing VMR. The threshold was measured twice (2-min interval), and the threshold mean was calculated as the data of the animals. The percentage change threshold, that is, the threshold value after treatment divided by the basal threshold value and multiplied by 100, was calculated.
Measuring colonic permeability. Colonic permeability measurement was performed as previously described. 17 The rats anesthetized by administration of the mixture of medetomidine hydrochloride (0.15 mg/kg), midazolam (2 mg/kg), and butorphanol tartrate (2.5 mg/kg) intraperitoneally (i.p.) were placed in a supine position on a heating pad, and laparotomy was performed. The colon was ligated at the junction with the cecum, and an open-tipped catheter (3-Fr, Atom, Tokyo, Japan) was inserted into the proximal colon through the hole made by a puncture using needle, and fixed by sutures. The colon was gently flushed with phosphate buffered saline (PBS) using the catheter, and another ligation was added on the colon at approximately 4 cm from the proximal ligation. Later, 1 mL of 1.5% Evans blue in PBS was instilled into the colon, and the animals were killed after 15 min. The colons were excised and washed with PBS and 1 mL of 6 mM N-acetyl-cysteine. Then, they were opened and placed in 2 mL of N,N-dimethylformamide for 12 h. Permeability was calculated by measuring the Evans blue concentration in the supernatant using a spectrophotometer at 610 nm.
Experimental procedures. First, the basal VMR threshold was measured. Then, the electrodes and distention balloon were removed, and either the vehicle or LPS (1 mg/kg) was subcutaneously (s.c.) injected (Fig. 1b) . The rats were returned to their home cages, and after 2.5 h, they underwent surgery for electrode implantation and balloon placement again. The second measurement of threshold was performed 3 h after the injection. 6 The vehicle or metformin (5, 10, or 50 mg/kg) was i.p. injected thrice at 48 h, 24 h, and 30 min before injecting LPS.
The effect of metformin on repeated WAS-induced allodynia was also evaluated (Fig. 1c) . 7 First, the basal threshold was measured, and either metformin or the vehicle was injected. Ten minutes later, either WAS or sham stress was applied for 1 h. These treatments, that is, injection and stress session, were implemented for three consecutive days. The threshold was again measured at 24 h after undergoing the last stress session. 7 Additionally, the drug injection was performed at 30 min before the second measurement.
Next, to explore the mechanisms of action of metformin, the effects of compound C (2 mg/kg s.c.), L-NAME (10 mg/kg i.p.), naloxone (1 mg/kg s.c.), sulpiride (200 mg/kg s.c.), or domperidone (10 mg/kg s.c.) were examined. These drugs were administered together with metformin.
In a separate series of experiments, effect of metformin on gut permeability was also explored. The permeability was determined 5 h after injecting LPS or 24 h after undergoing the last stress session.
Stress protocol. Exposure to WAS was performed as previously described. 18 Rats were individually placed on a plastic platform (height, 8 cm; length, 6 cm; and width, 6 cm) positioned in the middle of a plastic cage filled with water up to 7 cm of the platform height. Control animals were individually placed in the same plastic cage, which was not filled with water (sham stress).
Statistical analysis. Data are expressed as means ± standard error. Multiple comparisons were performed by one-way or twoway analysis of variance followed by Tukey's honestly significant difference test. Comparisons between two groups were performed using Student's t-test. The SYSTAT 13 software (Systat Software, Chicago, IL, USA) was used for the study. 
Results
Metformin eliminated lipopolysaccharide-induced or repeated water avoidance stress-induced visceral allodynia. Metformin per se did not alter the basal threshold of VMR (mL), that is, before injection of LPS or the vehicle (0.56 ± 0.016 for metformin at 50 mg/kg, n = 18 vs 0.56 ± 0.014 for vehicle, n = 18; P > 0.05). LPS significantly reduced the threshold of VMR, and metformin inhibited this response in a dose-responsive manner (F = 10.6, P < 0.05; Fig. 2a ). Metformin at 50 mg/kg fully reversed the response by LPS, and this dose was employed for the following experiments. Repeated WAS reduced the threshold significantly, and metformin blocked this response (effect of WAS: F = 14.1, P < 0.05; effect of metformin: F = 9.35, P < 0.05; and interaction between WAS and metformin: F = 13.3, P < 0.05; Fig. 2b ).
Compound C reversed the antinociceptive effect of metformin on lipopolysaccharide-induced visceral allodynia. Compound C did not alter the basal threshold (mL, 0.58 ± 0.019 for compound C, n = 10 vs 0.58 ± 0.020 for vehicle, n = 10; P > 0.05). Moreover, the treatment did not modify the response induced by LPS (effect of compound C: F = 2.35, P > 0.05; effect of LPS: F = 82.0, P < 0.05; and interaction between compound C and LPS: F = 0.186, P > 0.05).
Later, the effect of compound C on the antinociceptive effect of metformin was determined, and the drug abolished it (effect of compound C: F = 5.23, P < 0.05; effect of metformin: F = 5.0, P < 0.05; and interaction between compound C and metformin: F = 7.16, P < 0.05; Fig. 3 ).
N
G -nitro-L-arginine methyl ester reversed the antinociceptive effect of metformin. N G -nitro-L-arginine methyl ester did not change the basal threshold (mL, 0.57 ± 0.030 for L-NAME, n = 10 vs 0.56 ± 0.017 for vehicle, n = 11; P > 0.05). Furthermore, it did not alter the response by LPS (effect of L-NAME: F = 0.091, P > 0.05; effect of LPS: F = 40.4, P < 0.05; and interaction between L-NAME and LPS: F = 0.035, P > 0.05).
Next, we determined the effect of L-NAME on the antinociceptive effect of metformin, and it abolished the effect (effect of L-NAME: F = 12.5, P < 0.05; effect of metformin: F = 9.61, P < 0.05; and interaction between L-NAME and metformin: F = 9.09, P < 0.05; Fig. 4 ).
Naloxone did not alter the effect of metformin. Naloxone alter neither the basal threshold (mL, 0.59 ± 0.018 for naloxone, n = 10 vs 0.58 ± 0.015, n = 10; P > 0.05) nor the response by LPS (effect of naloxone: F = 0.42, P > 0.05; effect of LPS: F = 74.3, P < 0.05; and interaction between naloxone and LPS: F = 0.016, P > 0.05).
Additionally, naloxone did not modify the antinociceptive effect of metformin (effect of naloxone: F = 0.11, P > 0.05; effect of metformin: F = 51.3, P < 0.05; and interaction between naloxone and metformin: F = 0.025, P > 0.05; Fig. 5 ). Sulpiride blocked but domperidone did not alter the antinociceptive effect of metformin. Sulpiride altered neither the basal threshold (mL, 0.58 ± 0.019 for sulpiride, n = 10 vs 0.58 ± 0.020 for vehicle, n = 10; P > 0.05) nor the response by LPS (effect of sulpiride: F = 0.065, P > 0.05; effect of LPS: F = 22.3, P < 0.05; and interaction between sulpiride and LPS: F = 0.016, P > 0.05). Sulpiride abolished the antinociceptive effect of metformin (effect of sulpiride: F = 6.95, P < 0.05; effect of metformin: F = 8.95, P < 0.05; and interaction between sulpiride and metformin: F = 6.01, P < 0.05; Fig. 6a) , indicating that the effect of metformin was mediated via dopamine D2 receptor. Domperidone did not alter either the basal threshold (mL, 0.57 ± 0.021 for domperidone, n = 10 vs 0.58 ± 0.019 for vehicle, n = 10; P > 0.05) or the response by LPS (effect of domperidone: F = 0.31, P > 0.05; effect of LPS: F = 94.9, P < 0.05; and interaction between domperidone and LPS: F = 0.008, P > 0.05).
Furthermore, the drug did not modify the antinociceptive effect of metformin (effect of domperidone: F = 0.16, P > 0.05; effect of metformin: F = 38.9, P < 0.05; and interaction between domperidone and metformin: F = 0.65, P > 0.05; Fig. 6b ), suggesting that the effect of metformin was mediated via central dopamine D2 receptor.
Metformin inhibited the increased colonic permeability by lipopolysaccharide or repeated water avoidance stress. Metformin per se did not alter the permeability but blocked LPS-induced increased permeability (effect of LPS: F = 10.8, P < 0.05; effect of metformin: F = 8.14, P < 0.05; and interaction between LPS and metformin: F = 5.53, P < 0.05; Fig. 7a) . Moreover, the drug also abolished increased gut permeability induced by repeated WAS (effect of WAS: F = 6.59, P < 0.05; effect of metformin: F = 14.3, P < 0.05; and interaction between WAS and metformin: F = 14.1, P < 0.05; Fig. 7b ).
Discussion
We previously confirmed that visceral allodynia and increased colonic permeability induced by LPS or repeated WAS were mediated via pro-inflammatory cytokine. 6, 7 In the current study, we clearly showed for the first time that metformin blocked these visceral changes. Moreover, the antinociceptive effect of metformin , Vehicle; , Domperidone (10 mg/kg).
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was reversed by compound C, indicating that it is mediated via AMPK signaling. Toll-like receptor 4 (TLR4) detects LPS and stimulates nuclear factor-κB pathway resulting in the production of pro-inflammatory cytokines such as IL-1, IL-6, and tumor necrosis factor-α. 19 Several in vitro studies showed that LPS-induced inflammatory response was inhibited by AMPK. 20, 21 Metformin inhibits nuclear factor-κB activity to reduce the release of pro-inflammatory cytokine in human vascular smooth muscle cells, 11 and it suppresses LPS-induced production of the cytokine in murine macrophage. 12 These lines of evidence suggest that the antinociceptive effect of metformin in visceral pain may result from suppression of the cytokine signal via AMPK.
Recently, the importance of TLR4 signaling in IBS has been suggested. TLR4 in colonic tissue is elevated, 22 and TLR4 mRNA expression correlates significantly with duration of symptoms in the IBS patients. 23 Additionally, WAS significantly increases colonic TLR4 expression. 24 Enhanced signal intensity of TLR4 in colonic mucosa may increase immune response, leading to the development of a chronic intestinal inflammation and increased production of cytokines, 25 thereby possibly altering colonic functions. Incidentally, metformin suppresses TLR4 expression in the heart and the lung, 26, 27 which may raise the possibility that the effect of metformin is attributed to suppression of TLR4.
We also found that the effect of metformin was blocked by L-NAME. Activation of AMPK has an anti-atherosclerotic effect beyond the glycemic effect, and one of the mechanisms of the action was demonstrated to be NO-dependent pathway, 28 suggesting that the drug facilitates NO production. Besides, NO exerts an antinociceptive effect, 29 and the mechanism is thought to be that NO induces cyclic guanosine monophosphate generation to open ATP-sensitive K + channels, leading to hyperpolarizing nociceptive neurons. 30 It was reported that the glucose-lowering action of metformin was caused by an increase of β-endorphin secretion from adrenal glands to stimulate opioid μ-receptor, leading to an increase of GLUT-4 gene expression in skeletal muscle. 31 Therefore, we determined the role of opioid pathway, but it was not blocked by naloxone, indicating that antinociceptive effect of metformin was not mediated via opioid pathway.
We previously showed that central dopamine signaling plays a pivotal role in visceral pain. Intracisternal injection of dopamine agonist exerted antinociceptive action against colonic distention.
32
Moreover, single WAS session acutely induced visceral hyposensitivity, which was mediated via central dopamine D2 receptor. 33 In this context, we speculated some relation between antinociceptive effect of metformin and central dopamine D2 receptor, and it actually happened that sulpiride abolished but domperidone did not modify the effect of metformin.
There is no direct evidence indicating that metformin activates brain dopamine signaling. Metformin is known to rapidly cross the blood-brain barrier, and it is detected in the mouse brain after single oral administration of the drug at a dose of 50 mg/kg, which is similar dose used in the current study, 34 suggesting that metformin could act to the brain to exert the action. Actually, several studies have demonstrated that metformin can exhibit an antiinflammatory effect in the brain. 35, 36 Incidentally, metformin exacerbates and/or attenuates the stroke in experimental mice stroke model via neuronal NO synthase. 35 Moreover, NO enhances release of dopamine in nucleus accumbens, 37 and dopamine D1 and D2 receptors in the nucleus play an important role in antinociception. 38, 39 In this context, it may be considered that metformin acts to the brain to release NO, which may possibly activate dopamine neurons in the certain nucleus mediating pain response, thereby inducing antinociceptive action.
This study has several limitations. We did not show the direct evidence that metformin inhibited the production of cytokines. Although the visceral changes observed in the IBS models in the current study were mediated via IL-1 and IL-6 pathways, the colonic mucosal levels of these cytokines were not significantly elevated (data were not shown). Therefore, we could not explore the expected action of metformin. Various cells other than Figure 7 Effect of metformin on colonic permeability. Lipopolysaccharide (LPS) increased the permeability, which was blocked by metformin (a). The drug also abolished repeated water avoidance stress (WAS)-induced increased colonic permeability (b). Sham; sham stress. * P < 0.05 versus vehicle + vehicle or vehicle + sham, # P < 0.05 versus vehicle + LPS or vehicle + WAS by two-way analysis of variance followed by Tukey's honestly significant difference test. Each column represents the mean ± standard error. The number of rats examined is shown in parentheses.
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macrophage or monocyte, such as fibroblasts, endothelial, neuronal, and smooth muscle cells, secrete these cytokines, 40 but the sources responsible for the visceral changes were not determined. In addition, the antinociceptive effect of metformin was NO-dependent, but we did not directly show that NO synthesis was increased by the drug. Further studies are needed to determine the precise mechanisms of action in molecular and cellular levels.
As described before, metformin has been reported to have several pleiotropic effects beyond the glycemic control. 10 Despite the aforementioned limitations, we clearly demonstrated that metformin abolished visceral allodynia and improved gut burrier in rat IBS models, which seemed to be novel pleiotropic effects. Moreover, effective dose was 50 mg/kg, which is a nearly equivalent to the human clinical dose. Because metformin is one of the most commonly prescribed to the patients with diabetes, their application to IBS treatment seems not to be difficult. Large-scale clinical trials to explore the effectiveness of metformin in the patients with IBS should be conducted in future.
In summary, metformin blocked visceral allodynia and increased colonic permeability induced by LPS or repeated WAS, which may be AMPK-dependent response, and mediated via NO and central dopamine D2 pathways. Metformin may be useful for IBS treatment.
